BIOCORP Signs New Partnership Around InspairTM With H&T Presspart
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announces today the signature of a new agreement with H&T Presspart (a division of the German-based Heitkamp & Thumann Group), whereby H&T Presspart is licenced to sell and promote BIOCORP’s InspairTM smart add-on device for metered-dose inhalers.
The partnership covers the integration and commercialization of InspairTM, a smart sensor designed by BIOCORP that transforms inhalers into connected devices to help patients suffering from asthma or chronic obstructive pulmonary disease (COPD) in the delivery of their treatment.
This partnership will allow BIOCORP to integrate its connected solution with the most popular inhalers on the market, while leveraging its partner's extensive sales network to distribute InspairTM. With this solution, H&T Presspart, the market leader in respiratory drug delivery devices (1,2 billion devices and cans produced each year, 85% of market share), will be able to expand its product portfolio in the field of digital healthcare solutions beyond its existing embedded eMDITM platform with an add-on device that will improve patient adherence and will help patients to manage their conditions more effectively.
Christian Kraetzig, President of H&T Presspart commented: “This strategic partnership underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for patients”.
Eric Dessertenne, CEO of BIOCORP added: "We are very proud to entrust the distribution of InspairTM to H&T Presspart, one of the world leaders in the respiratory disease market. This new major agreement further positions BIOCORP as a provider of connected health solutions. After our success with MallyaTM, BIOCORP now has a second solution with very high potential both in terms of business and the number of possible applications with InspairTM”.
InspairTM provides an innovative and effective response to the needs of these two diseases: it directly affects compliance with treatment and strengthens the link between the patient and the medical staff by providing real-time therapeutic monitoring. This smart sensor converts any pressurized metered dose inhaler into a connected device. InspairTM records daily inhalation data, monitors proper aerosol preparation (which must be shaken before use), assesses inhalation timing (hand-to-mouth coordination) and provides useful insights into the various stages of inhalation.
ABOUT H&T PRESSPART
H&T Presspart is a market leader in the design and manufacture of respiratory drug delivery systems, with 50 years’ experience and a worldwide reputation for competence, quality and innovation in the pharmaceutical market. H&T Presspart’s New Product Development Center (NPDC) & Inhalation Product Technology Centre (IPTC) support new product developments and strategic initiatives with our customers. Founded in 1970 and acquired by the Heitkamp & Thumann group in 2002, H&T Presspart has 4 European manufacturing sites with additional sales offices in China, India, the U.S.A. and Uruguay. For more information, please visit www.presspart.com.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005759/en/
Contact information
BIOCORP
Sylvaine Dessard
Senior Director Marketing & Communication
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
Bruno ARABIAN
Press Officer
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
H&T PRESSPART
Chad Mayoh
chad.mayoh@presspart.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Publishes 2025 ESG Progress Report: Advancing Integrity, Innovation, and Impact23.10.2025 23:05:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2025 Environmental, Social, and Governance (ESG) Progress Report, covering its progress in 2024 and underscoring the company’s commitment to responsible business, data integrity, and inclusive growth across its global operations. “As a leading consumer intelligence company, our responsibility extends far beyond the industries we serve,” said Jim Peck, Executive Chairman and CEO of NIQ. “This year’s ESG Progress Report demonstrates how we are embedding sustainable and inclusive principles into our business, driving value for our clients, investors, associates, and communities.” Key progress areas from 2024 Strengthened ESG governance: NIQ formalized its internal ESG governance framework and initiated a Double Materiality Assessment, aligning with the latest global standards and regulations. Advanced data integrity and security: The company advanced its use of AI and machine learning to ensure data quality, priv
Berry Consultants Releases FACTS 8 Clinical Trial Simulator23.10.2025 20:00:00 EEST | Press release
Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/ FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements: Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis. A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provides for more customized adaptive designs. “Ordinal endpoints are ubiquitous in clin
KORJAA JA KORVAA: Tosi nimittää Jussi Postin talousjohtajaksi23.10.2025 18:38:00 EEST | Tiedote
Kyberfyysisten järjestelmien johtava toimittaja Tosi ilmoitti, että Jussi Posti aloittaa välittömästi yhtiön talousjohtajana. Posti ottaa vastuun Tosin kansainvälisestä taloushallinnosta ja strategisesta suunnittelusta, kun yhtiö jatkaa nopeaa kasvuaan uudelleenbrändäyksen ja tilaussopimusten 70 prosentin kasvun myötä. "Jussilla on ainutlaatuista kokemusta Fortune 500 -yhtiöiden talousjohtamisesta ja yrittäjämäisestä ajattelusta, mikä tekee hänestä ihanteellisen valinnan johtamaan Tosia seuraavassa kasvuvaiheessa", kertoo Sakari Suhonen, Tosin Yhdysvaltain toimitusjohtaja. "Hänen laajalla kokemuksellaan on ratkaiseva merkitys, kun uudistamme tapaa, jolla organisaatiot yhdistävät, suojaavat ja hallitsevat kriittisiä infrastruktuurejaan." Posti siirtyy Tosille toimittuaan lähes viiden vuoden ajan Microsoft Suomen talousjohtajana. Aiemmin hän on toiminut talousjohtajana Schneider Electricillä Suomessa ja Baltiassa. "Tosin muuntautuminen kyberfyysisten järjestelmien tarjoajaksi on valtava
Saudi Arabia to Host 26 th UN Tourism General Assembly in November Marking Agency’s 50 th Year23.10.2025 17:58:00 EEST | Press release
The Kingdom of Saudi Arabia will host the 26th session of the UN Tourism General Assembly from November 7 to 11. The landmark session will focus on “AI-Powered Tourism: Redefining the Future” and also commemorate five decades of cooperation under the United Nations’ specialized agency for tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022579574/en/ Riyadh Nighttime View Represented by its Ministry of Tourism, Saudi Arabia will welcome more than 160 member states, international organizations, and global industry players to engage in dialogue aimed at securing a brighter, more sustainable future for the industry and shaping the next 50 years of global tourism. Saudi Arabia’s Minister of Tourism, H.E. Ahmed Al Khateeb, invited the world to Riyadh to take part in a momentous milestone for global tourism diplomacy: “We look forward to hosting the world’s leading organization for tourism in a session that will redefine
Macrobond and FactSet Collaborate to Deliver Direct Access to Global Equity Data on a Single Integrated Research Platform23.10.2025 16:49:00 EEST | Press release
Macrobond, the leading provider of global economic and financial data and analytics, today announced a strategic integration with FactSet, a global digital platform and enterprise solutions provider. This collaboration provides Macrobond users with direct access to FactSet’s extensive equity and ETF datasets—including fundamentals, consensus estimates, market aggregates, and equity prices and returns —within the Macrobond platform. By combining Macrobond’s top-down macroeconomic insights with FactSet’s bottom-up company analysis, this collaboration delivers a uniquely complementary dataset that empowers clients to seamlessly integrate global economic trends with detailed security-level intelligence. This integration creates a seamless environment for economists, strategists, and analysts to analyze equity data with the efficiency and precision that define Macrobond’s approach to economic intelligence. The result enables enhanced decision-making, empowering users to drive smarter invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom